Search for stock quotes, financial statistics and more
Andre Uddin of Research Capital maintained a “Speculative Buy” rating and C$14.00 price target o... Read More
In a Nov. 5 update, Research Capital analyst André Uddin reiterated his “Speculative Buy” ratin... Read More
Leede Financial has initiated coverage of Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Q... Read More
Research Capital analyst Andre Uddin reiterated a “Speculative Buy” rating and C$12.00 target pr... Read More
Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$12.00 target pr... Read More
Share
Tweet
pin
Share